No Prescription |
 |
 | ||
|
Trisul Paediatric Sugar Free Septra |
|
| ||
No Prescription » Prescription Drugs 16 » Trisul Paediatric Sugar Free Septra TRISUL should only be used where in the judgement of the physician the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent. The in vitro susceptibility of bacteria to antibiotics varies geographically and with time; the local situation should always be considered when selecting antibiotic therapy.Urinary tract infectionsTreatment of acute uncomplicated urinary tract infections. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.Respiratory tract infectionsTreatment of otitis media. TRISUL is not indicated for prophylactic or prolonged administration in otitis media.Treatment of acute exacerbations of chronic bronchitis.Treatment and prevention of Pneumocystis Jirovecii. (See Dosage and Administration and Adverse Effects).Other bacterial infections caused by sensitive organismsThere are a number of other bacterial infections caused by sensitive organisms for which treatment with TRISUL may be appropriate; the use of TRISUL in such conditions should be based on clinical experience and local in vitro data.Treatment and prophylaxis of toxoplasmosis treatment of nocardiosis.Dosage and AdministrationIt may be preferable to take TRISUL with some food or drink to minimise the possibility of gastrointestinal disturbances.Acute InfectionsChildren aged 12 years and underAge Paediatric Suspension 6 to 12 years 10 ml every 12 hours 6 months to 5 years 5 ml every 12 hours 6 weeks to 5 months 2.5 ml every 12 hours This dosage approximates to 6 mg trimethoprim and 30 mg sulfamethoxazole per kilogram body weight per 24 hours.Treatment should be continued until the patient has been symptom free for two days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days' therapy the patient should be reassessed.As an alternative to STANDARD DOSAGE for acute uncomplicated lower urinary tract infections short term therapy of 1 to 3 days' duration has been shown to be effective. Buy Trisul Paediatric Sugar Free Septra and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Trisul Paediatric Sugar Free Septra: Product Type: Prescription Drugs 16 Trisul Paediatric Sugar Free ( Septra Generic Co-trimoxazole (Trimethoprim/Sulfamethoxazole) ) Trisul Paediatric Sugar Free (Septra Generic Co-trimoxazole) Septra Generic Co-trimoxazole 40/200mg/5mL Septra Generic Co-trimoxazole Trisul Paediatric Sugar Free
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
